Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144760 | 0.83 | ACACB (0.40) | ACACBACACAEPHA2KDREPHB4 | |
| SCHEMBL4141349 | 0.83 | ACACB (0.40) | ACACBACACAEPHA2KDREPHB4 | |
| SCHEMBL6322635 | 0.82 | KMT2A (0.45) | NPC1RAB9AKMT2AACACBACACA | |
| SCHEMBL6331356 | 0.76 | MAP4K4 (0.49) | — | |
| SCHEMBL6330326 | 0.75 | ADORA2A (0.45) | HSD11B1 | |
| SCHEMBL20202126 | 0.75 | ACACB (0.39) | HCRTR1ACACBACACAGRM5HCRTR2 | |
| SCHEMBL487434 | 0.73 | HCRTR1 (0.43) | HCRTR1KMT2AACACBACACAHCRTR2 | |
| SCHEMBL5109524 | 0.73 | HSD11B1 (0.42) | HCRTR1ACACBACACAHCRTR2HSD11B1 | |
| SCHEMBL12810004 | 0.70 | DRD2 (0.43) | ACACBACACA | |
| SCHEMBL3083501 | 0.70 | EPHX1 (0.44) | HCRTR1KMT2AMEN1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-19 | — | — | US | disclosed |
| WO-2004080970-A1 | NOVEL BICYCLIC AROMATIC COMPOUNDS, THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107409-A1 | Aromatic bicyclic compounds, preparation thereof and their use as pharmaceutical compositions | F12, F2, F11 | HCRTR1 2052/4885NPC1 1892/4885RAB9A 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.